IMMUNOLOGICAL BLOOD SAMPLE PREPARATION AND ASSAYS

NIH GUIDE, Volume 23, Number 2, January 14, 1994



RFP AVAILABLE:  NCI-CB-46207-82



P.T. 34



Keywords:

  Cancer/Carcinogenesis 

  Vaccine 

  Bioassay 



National Cancer Institute



The National Cancer Institute (NCI) is soliciting proposals from

offerors with the capability to provide immunological testing support

services in the cancer vaccine field.  Testing will be of patient

and/or non-human primate blood.  The assays required will include:

isolation and freezing of peripheral blood mononuclear cells,

lymphoproliferation assays, cytolkine assays, T cell phenotyping,

cytotoxic T cell assays, and assays for antigen, antibody, and

antigen-antibody complexes.  This is a new requirement.  Some limited

testing has been provided through the use of purchase orders.



The first recombinant anti-cancer vaccine developed by the NCI has

already begun Phase 1 clinical trails.  There are other recombinant

anti-cancer vaccines that will also be tested in non-human primates

and in clinical trials.  Common to all these trials and preclinical

testing is the fact that active specific immunotherapy approaches are

based on the potentiation of the cellular and/or the humoral immune

response by active immunization, the induction of cellular and/or

humoral responses, and the subsequent role of the antitumor activity.

This information is critical to evaluation of the vaccines.  This

necessitates a comprehensive and uniform evaluation of the

immunological responses, since many of these studies will be carried

out at different institutions and companies.



The Government will supply patient and/or non-human primate blood to

the contractor for analysis.  These samples will be identified by

code to ensure patient confidentiality and blinded analysis.  Blood

analyses are separated into the following tests:  (1) isolation and

freezing of peripheral blood mononuclear cells; (2) immunoresponse

assays including:  (2a) lymphoproliferation assays, (2b) culture

supernatant harvets, (2c) cytokine assays (IL-2, IL-6, IFN-gamma,

TNF-alpha); (3) T cell phenotyping (CD3, CD4, CD8, CD4/C); (4)

cytotoxic cell assays including; (4a) generation of EBV immortalized

B cell lines, (4b) preparation of target cells, (4c) preparation of

effector cells, (4d) cytotoxic assays; (5) serologic assays

including:  (5a) separation of serum from blood samples, (5b)

anti-tumor associated antigen immunoglobulin response, (5c) serum

tumor associated antigen levels, (5d) immune complex determination.

The NCI project officer will order the assays to be performed on each

individual [BLOOD] sample.  The orders, therefore, may be only one

assay of all of the above, per individual sample.  It is anticipated

that the proposed contract will be for a five-year period of

performance.



INQUIRIES



Solicitation will be issued on or about January 12, 1994, and

responses will be due 30 days thereafter.  All responsible sources

may submit a proposal that will be considered by the NCI.  No collect

calls will be accepted.  Requests for this solicitation must be in

writing and reference NCI-CB-46207-82.  Requests are to be addressed

and mailed or faxed to:



Michelle Scala

Research Contracts Branch, PSCS

National Cancer Institute

Executive Plaza South, Room 638

Bethesda, MD  20892

Telephone:  (301) 402-4509

FAX:  (301) 402-4513



.

Return to 1994 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)